View Older Stories

May 1, 2026 04:36PM Vanda launches motion sickness drug NEREUS after 40-year gap

Apr 9, 2026 11:03AM Vanda Pharmaceuticals opposes FDA proposal to extend drug review timelines

Apr 9, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Apr 8, 2026 04:45PM Vanda starts trial of NEREUS drug for GLP-1 side effects

Mar 27, 2026 11:24AM Truist Securities on Vanda Pharmaceuticals (VNDA): EMA news is just 'noise'

Mar 5, 2026 06:03AM Truist Securities Starts Vanda Pharmaceuticals (VNDA) at Buy

Mar 3, 2026 08:03AM FDA grants Vanda formal hearing on HETLIOZ jet lag application

Feb 25, 2026 07:19AM FDA accepts Vanda's drug application for rare skin disorder treatment

Feb 23, 2026 10:38AM Increasing unusual call option volume: PBRA EC BGS IBRX IGV AUTL VNDA GRAL FSLY PRGS EWJ ATOM VICR XLU EDIT

Feb 23, 2026 06:36AM Vanda Pharmaceuticals (VNDA) PT Raised to $24 at H.C. Wainwright

Feb 23, 2026 05:19AM Vanda Pharmaceuticals (VNDA) call put ratio 4.2 calls to 1 put into announces FDA approval of Bysanti tablets

Feb 20, 2026 04:22PM Vanda Pharmaceuticals (VNDA) halted, news pending

Feb 12, 2026 07:21AM Vanda Pharmaceuticals (VNDA) files $200M mixed shelf

Feb 11, 2026 04:03PM Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 83c, provides guidance

Jan 8, 2026 07:01AM FDA rejects Vanda's HETLIOZ application for jet lag disorder

Jan 5, 2026 06:41AM Vanda Pharmaceuticals (VNDA) PT Raised to $22 at H.C. Wainwright

Dec 31, 2025 03:12PM Vanda Pharmaceuticals (VNDA) call put ratio 9.7 calls to 1 puts with a focus on January 8 and 9 calls

Dec 31, 2025 10:13AM Increasing unusual option volume: EWC VNDA TKO XERS CORT ZSL BXSL OTLK PSQ CDZI

Dec 31, 2025 04:25AM Vanda Pharmaceuticals (VNDA) PT Raised to $7.50 at Jefferies

Dec 17, 2025 07:30AM Vanda Pharmaceuticals (VNDA) Reiterated at Outperform by Cantor Fitzgerald

Dec 15, 2025 07:01AM Vanda submits FDA application for rare skin disorder drug

Dec 4, 2025 04:22PM FDA lifts clinical hold on Vanda's motion sickness drug tradipitant

Dec 1, 2025 06:35AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Nov 28, 2025 07:00AM Vanda gets FDA extension for tradipitant motion sickness drug review

Nov 5, 2025 02:42AM B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy

Oct 29, 2025 04:05PM Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 5c ; Offers Guidance

Oct 28, 2025 03:07PM Vanda Pharmaceuticals (VNDA) 2300 contracts of January 6 calls trade

Oct 2, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Oct 1, 2025 05:03PM Vanda Pharmaceuticals reaches dispute resolution framework with FDA

Sep 25, 2025 08:03AM Vanda publishes study showing HETLIOZ improved sleep in insomnia patients

Aug 28, 2025 07:00AM Vanda Pharmaceuticals receives FDA orphan drug status for polycythemia vera drug

Aug 21, 2025 04:40PM Vanda requests FDA commissioner review of generic Hetlioz approvals

Aug 21, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Aug 18, 2025 07:01AM Federal appeals court overturns FDA denial of Vanda's jet lag drug

Jul 31, 2025 07:46AM Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance

May 14, 2025 09:03AM Cantor Fitzgerald Reiterates Overweight Rating on Vanda Pharmaceuticals (VNDA)

May 7, 2025 04:12PM Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c, provides guidance

May 5, 2025 08:00AM Vanda Pharmaceuticals (VNDA) Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026

Apr 23, 2025 03:57PM Vanda Pharmaceuticals (VNDA): FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Mar 31, 2025 08:00AM Vanda Pharmaceuticals (VNDA) Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Mar 19, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Mar 13, 2025 06:58AM Cantor Biotech industry report, buying value in RevGens

Feb 24, 2025 07:06AM Vanda Pharmaceuticals (VNDA) announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 18, 2025 06:44AM Vanda Pharmaceuticals (VNDA) PT Raised to $20 at H.C. Wainwright

Feb 14, 2025 07:06AM Cantor Fitzgerald Reiterates Overweight Rating on Vanda Pharmaceuticals (VNDA)

Feb 13, 2025 04:03PM Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 9c ; Offers Guidance

Feb 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Feb 3, 2025 07:30AM Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab

Jan 28, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

Jan 27, 2025 07:18AM Vanda Pharmaceuticals (VNDA) Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

View Older Stories